1. Home
  2. RANI vs PCLA Comparison

RANI vs PCLA Comparison

Compare RANI & PCLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RANI
  • PCLA
  • Stock Information
  • Founded
  • RANI 2012
  • PCLA 2008
  • Country
  • RANI United States
  • PCLA Japan
  • Employees
  • RANI N/A
  • PCLA N/A
  • Industry
  • RANI Medicinal Chemicals and Botanical Products
  • PCLA Building Products
  • Sector
  • RANI Health Care
  • PCLA Consumer Discretionary
  • Exchange
  • RANI Nasdaq
  • PCLA Nasdaq
  • Market Cap
  • RANI 23.2M
  • PCLA 18.6M
  • IPO Year
  • RANI 2021
  • PCLA 2025
  • Fundamental
  • Price
  • RANI $0.47
  • PCLA $0.50
  • Analyst Decision
  • RANI Strong Buy
  • PCLA
  • Analyst Count
  • RANI 4
  • PCLA 0
  • Target Price
  • RANI $7.75
  • PCLA N/A
  • AVG Volume (30 Days)
  • RANI 413.1K
  • PCLA 199.5K
  • Earning Date
  • RANI 11-13-2025
  • PCLA 01-01-0001
  • Dividend Yield
  • RANI N/A
  • PCLA N/A
  • EPS Growth
  • RANI N/A
  • PCLA N/A
  • EPS
  • RANI N/A
  • PCLA N/A
  • Revenue
  • RANI $1,200,000.00
  • PCLA $5,475,228.00
  • Revenue This Year
  • RANI N/A
  • PCLA N/A
  • Revenue Next Year
  • RANI N/A
  • PCLA N/A
  • P/E Ratio
  • RANI N/A
  • PCLA N/A
  • Revenue Growth
  • RANI N/A
  • PCLA 40.19
  • 52 Week Low
  • RANI $0.39
  • PCLA $0.37
  • 52 Week High
  • RANI $3.75
  • PCLA $9.80
  • Technical
  • Relative Strength Index (RSI)
  • RANI 41.49
  • PCLA 46.55
  • Support Level
  • RANI $0.47
  • PCLA $0.42
  • Resistance Level
  • RANI $0.51
  • PCLA $0.55
  • Average True Range (ATR)
  • RANI 0.04
  • PCLA 0.04
  • MACD
  • RANI -0.00
  • PCLA 0.02
  • Stochastic Oscillator
  • RANI 21.26
  • PCLA 63.36

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

About PCLA PicoCELA Inc. American Depositary Shares

PicoCELA Inc specializes in manufacturing, installing, and servicing enterprise wireless mesh solutions. The company generates revenue from two main sources: product equipment sales, and Software as a Service (SaaS) and maintenance services. The company develops the PCWL series of mesh Wi-Fi access points, which utilize its proprietary PicoCELA Backhaul Engine (PBE) technology to enable wireless communication. The company outsources manufacturing and sells these devices directly to customers through distributors. Additionally, the company offers a cloud portal service in a SaaS model, allowing users to monitor connectivity and traffic at their access points. This platform also supports the installation of proprietary edge-computing software into the devices.

Share on Social Networks: